Mutations Beyond BRAF V600
Mollie Reed, MSN, ACNP-BC
Tennessee Oncology, Nashville, Tennessee
Author’s disclosures of conflicts of interest are found at the end of this article.
Mollie Reed, MSN, ACNP-BC, 250 25th Ave North, Suite 100/200, Nashville, TN 37203. E-mail: email@example.com
J Adv Pract Oncol 2018;9(suppl 1):39–45 |
© 2018 Harborside™
Among mutations in melanoma, BRAF V600 mutations have historically attracted the most attention and research. However, NRAS, GNAQ, c-KIT, NF1, and atypical BRAF mutations, although less common, warrant identification and consideration. Although consensus guidelines for the treatment and management of these other, non–BRAF V600 mutations are unavailable to date, there has been increased interest in evaluating effective treatments in these subgroups. This article explores the incidence, risk factors, and clinical studies involving these other, less frequent mutations in melanoma to provide guidance and considerations regarding appropriate testing and management of melanomas harboring these mutations.
For access to the full length article, please sign in